438 related articles for article (PubMed ID: 30531922)
1. The molecular landscape of glioma in patients with Neurofibromatosis 1.
D'Angelo F; Ceccarelli M; Tala ; Garofano L; Zhang J; Frattini V; Caruso FP; Lewis G; Alfaro KD; Bauchet L; Berzero G; Cachia D; Cangiano M; Capelle L; de Groot J; DiMeco F; Ducray F; Farah W; Finocchiaro G; Goutagny S; Kamiya-Matsuoka C; Lavarino C; Loiseau H; Lorgis V; Marras CE; McCutcheon I; Nam DH; Ronchi S; Saletti V; Seizeur R; Slopis J; Suñol M; Vandenbos F; Varlet P; Vidaud D; Watts C; Tabar V; Reuss DE; Kim SK; Meyronet D; Mokhtari K; Salvador H; Bhat KP; Eoli M; Sanson M; Lasorella A; Iavarone A
Nat Med; 2019 Jan; 25(1):176-187. PubMed ID: 30531922
[TBL] [Abstract][Full Text] [Related]
2. Telomere alterations in neurofibromatosis type 1-associated solid tumors.
Rodriguez FJ; Graham MK; Brosnan-Cashman JA; Barber JR; Davis C; Vizcaino MA; Palsgrove DN; Giannini C; Pekmezci M; Dahiya S; Gokden M; Noë M; Wood LD; Pratilas CA; Morris CD; Belzberg A; Blakeley J; Heaphy CM
Acta Neuropathol Commun; 2019 Aug; 7(1):139. PubMed ID: 31462295
[TBL] [Abstract][Full Text] [Related]
3. Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.
Lucas CG; Sloan EA; Gupta R; Wu J; Pratt D; Vasudevan HN; Ravindranathan A; Barreto J; Williams EA; Shai A; Whipple NS; Bruggers CS; Maher O; Nabors B; Rodriguez M; Samuel D; Brown M; Carmichael J; Lu R; Mirchia K; Sullivan DV; Pekmezci M; Tihan T; Bollen AW; Perry A; Banerjee A; Mueller S; Gupta N; Hervey-Jumper SL; Oberheim Bush NA; Daras M; Taylor JW; Butowski NA; de Groot J; Clarke JL; Raleigh DR; Costello JF; Phillips JJ; Reddy AT; Chang SM; Berger MS; Solomon DA
Acta Neuropathol; 2022 Oct; 144(4):747-765. PubMed ID: 35945463
[TBL] [Abstract][Full Text] [Related]
4. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations.
Reinhardt A; Stichel D; Schrimpf D; Sahm F; Korshunov A; Reuss DE; Koelsche C; Huang K; Wefers AK; Hovestadt V; Sill M; Gramatzki D; Felsberg J; Reifenberger G; Koch A; Thomale UW; Becker A; Hans VH; Prinz M; Staszewski O; Acker T; Dohmen H; Hartmann C; Mueller W; Tuffaha MSA; Paulus W; Heß K; Brokinkel B; Schittenhelm J; Monoranu CM; Kessler AF; Loehr M; Buslei R; Deckert M; Mawrin C; Kohlhof P; Hewer E; Olar A; Rodriguez FJ; Giannini C; NageswaraRao AA; Tabori U; Nunes NM; Weller M; Pohl U; Jaunmuktane Z; Brandner S; Unterberg A; Hänggi D; Platten M; Pfister SM; Wick W; Herold-Mende C; Jones DTW; von Deimling A; Capper D
Acta Neuropathol; 2018 Aug; 136(2):273-291. PubMed ID: 29564591
[TBL] [Abstract][Full Text] [Related]
5. Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1).
Fisher MJ; Jones DTW; Li Y; Guo X; Sonawane PS; Waanders AJ; Phillips JJ; Weiss WA; Resnick AC; Gosline S; Banerjee J; Guinney J; Gnekow A; Kandels D; Foreman NK; Korshunov A; Ryzhova M; Massimi L; Gururangan S; Kieran MW; Wang Z; Fouladi M; Sato M; Øra I; Holm S; Markham SJ; Beck P; Jäger N; Wittmann A; Sommerkamp AC; Sahm F; Pfister SM; Gutmann DH
Acta Neuropathol; 2021 Apr; 141(4):605-617. PubMed ID: 33585982
[TBL] [Abstract][Full Text] [Related]
6. Subependymal giant cell astrocytoma-like astrocytoma: a neoplasm with a distinct phenotype and frequent neurofibromatosis type-1-association.
Palsgrove DN; Brosnan-Cashman JA; Giannini C; Raghunathan A; Jentoft M; Bettegowda C; Gokden M; Lin D; Yuan M; Lin MT; Heaphy CM; Rodriguez FJ
Mod Pathol; 2018 Dec; 31(12):1787-1800. PubMed ID: 29973652
[TBL] [Abstract][Full Text] [Related]
7. Genotype-phenotype associations in neurofibromatosis type 1 (NF1): an increased risk of tumor complications in patients with NF1 splice-site mutations?
Alkindy A; Chuzhanova N; Kini U; Cooper DN; Upadhyaya M
Hum Genomics; 2012 Aug; 6(1):12. PubMed ID: 23244495
[TBL] [Abstract][Full Text] [Related]
8. Frequent alternative lengthening of telomeres and ATRX loss in adult NF1-associated diffuse and high-grade astrocytomas.
Rodriguez FJ; Vizcaino MA; Blakeley J; Heaphy CM
Acta Neuropathol; 2016 Nov; 132(5):761-763. PubMed ID: 27650176
[No Abstract] [Full Text] [Related]
9. The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.
Solga AC; Toonen JA; Pan Y; Cimino PJ; Ma Y; Castillon GA; Gianino SM; Ellisman MH; Lee DY; Gutmann DH
Oncotarget; 2017 Jul; 8(29):47206-47215. PubMed ID: 28525381
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors.
Upadhyaya M; Han S; Consoli C; Majounie E; Horan M; Thomas NS; Potts C; Griffiths S; Ruggieri M; von Deimling A; Cooper DN
Hum Mutat; 2004 Feb; 23(2):134-146. PubMed ID: 14722917
[TBL] [Abstract][Full Text] [Related]
11. NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1.
Toonen JA; Anastasaki C; Smithson LJ; Gianino SM; Li K; Kesterson RA; Gutmann DH
Hum Mol Genet; 2016 May; 25(9):1703-13. PubMed ID: 26908603
[TBL] [Abstract][Full Text] [Related]
12. An update on the central nervous system manifestations of neurofibromatosis type 1.
Nix JS; Blakeley J; Rodriguez FJ
Acta Neuropathol; 2020 Apr; 139(4):625-641. PubMed ID: 30963251
[TBL] [Abstract][Full Text] [Related]
13. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
14. Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations.
Shibahara I; Sonoda Y; Suzuki H; Mayama A; Kanamori M; Saito R; Suzuki Y; Mashiyama S; Uenohara H; Watanabe M; Kumabe T; Tominaga T
Brain Tumor Pathol; 2018 Jan; 35(1):10-18. PubMed ID: 29138945
[TBL] [Abstract][Full Text] [Related]
15. Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1.
Sievers P; Appay R; Schrimpf D; Stichel D; Reuss DE; Wefers AK; Reinhardt A; Coras R; Ruf VC; Schmid S; de Stricker K; Boldt HB; Kristensen BW; Petersen JK; Ulhøi BP; Gardberg M; Aronica E; Hasselblatt M; Brück W; Bielle F; Mokhtari K; Lhermitte B; Wick W; Herold-Mende C; Hänggi D; Brandner S; Giangaspero F; Capper D; Rushing E; Wesseling P; Pfister SM; Figarella-Branger D; von Deimling A; Sahm F; Jones DTW
Acta Neuropathol; 2019 Sep; 138(3):497-504. PubMed ID: 31250151
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic implications of NF1 gene alterations in diffuse gliomas.
Vizcaíno MA; Shah S; Eberhart CG; Rodriguez FJ
Hum Pathol; 2015 Sep; 46(9):1323-30. PubMed ID: 26190195
[TBL] [Abstract][Full Text] [Related]
17. Neurological malignancies in neurofibromatosis type 1.
Eoli M; Saletti V; Finocchiaro G
Curr Opin Oncol; 2019 Nov; 31(6):554-561. PubMed ID: 31436563
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma.
Dasgupta B; Yi Y; Hegedus B; Weber JD; Gutmann DH
Cancer Res; 2005 Nov; 65(21):9843-50. PubMed ID: 16267007
[TBL] [Abstract][Full Text] [Related]
19. Clinical presentation and prognostic indicators in 100 adults and children with neurofibromatosis 1 associated non-optic pathway brain gliomas.
Byrne S; Connor S; Lascelles K; Siddiqui A; Hargrave D; Ferner RE
J Neurooncol; 2017 Jul; 133(3):609-614. PubMed ID: 28593402
[TBL] [Abstract][Full Text] [Related]
20. Clinical, histological, and molecular features of gliomas in adults with neurofibromatosis type 1.
Romo CG; Piotrowski AF; Campian JL; Diarte J; Rodriguez FJ; Bale TA; Dahiya S; Gutmann DH; Lucas CG; Prichett L; Mellinghoff I; Blakeley JO
Neuro Oncol; 2023 Aug; 25(8):1474-1486. PubMed ID: 36840626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
